These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 22089535)
21. Aliskiren, the future of renin-angiotensin system blockade? Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914 [TBL] [Abstract][Full Text] [Related]
22. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Feldman DL Hypertens Res; 2010 Apr; 33(4):279-87. PubMed ID: 20203685 [TBL] [Abstract][Full Text] [Related]
23. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction). Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717 [TBL] [Abstract][Full Text] [Related]
24. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Hans-Henrik P J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):118-21. PubMed ID: 21824990 [TBL] [Abstract][Full Text] [Related]
25. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level. Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841 [TBL] [Abstract][Full Text] [Related]
26. Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome. Wang W; Luo R; Lin Y; Wang F; Zheng P; Levi M; Yang T; Li C Am J Physiol Renal Physiol; 2015 Apr; 308(8):F910-22. PubMed ID: 25694485 [TBL] [Abstract][Full Text] [Related]
27. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice. Pöss J; Werner C; Lorenz D; Gensch C; Böhm M; Laufs U Basic Res Cardiol; 2010 Nov; 105(6):725-35. PubMed ID: 20857126 [TBL] [Abstract][Full Text] [Related]
28. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. Iwai M; Kanno H; Tomono Y; Inaba S; Senba I; Furuno M; Mogi M; Horiuchi M J Hypertens; 2010 Jul; 28(7):1471-81. PubMed ID: 20543712 [TBL] [Abstract][Full Text] [Related]
29. Mechanistic insights into the antifibrotic activity of aliskiren in the kidney. Zeisberg M; Müller GA Hypertens Res; 2012 Mar; 35(3):266-8. PubMed ID: 22258024 [No Abstract] [Full Text] [Related]
30. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696 [TBL] [Abstract][Full Text] [Related]
31. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271 [TBL] [Abstract][Full Text] [Related]
32. Renin inhibition in hypertension. Gradman AH; Kad R J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679 [TBL] [Abstract][Full Text] [Related]
33. [Renin inhibition in hypertension]. Güleç S Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():15-22. PubMed ID: 20019472 [TBL] [Abstract][Full Text] [Related]
34. [Advantages and limitations of renin inhibition with aliskiren]. Azizi M; Frank M; Steichen O; Blanchard A Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538 [TBL] [Abstract][Full Text] [Related]
35. Managing cardiovascular and renal risk: the potential of direct renin inhibition. Sever PS; Gradman AH; Azizi M J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253 [TBL] [Abstract][Full Text] [Related]
36. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. Dalla Vestra M; Simioni N; Masiero A Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162 [TBL] [Abstract][Full Text] [Related]
37. Renoprotective effect of aliskiren on renal ischemia/reperfusion injury in rats: electron microscopy and molecular study. Ziypak T; Halici Z; Alkan E; Akpinar E; Polat B; Adanur S; Cadirci E; Ferah I; Bayir Y; Karakus E; Mercantepe T Ren Fail; 2015 Mar; 37(2):343-54. PubMed ID: 25524622 [TBL] [Abstract][Full Text] [Related]
38. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Wu WP; Chang CH; Chiu YT; Ku CL; Wen MC; Shu KH; Wu MJ Am J Physiol Renal Physiol; 2010 Nov; 299(5):F929-41. PubMed ID: 20685818 [TBL] [Abstract][Full Text] [Related]
39. Direct renin inhibition with aliskiren improves ischemia-induced neovascularization: blood pressure-independent effect. Desjarlais M; Dussault S; Dhahri W; Mathieu R; Rivard A Atherosclerosis; 2015 Oct; 242(2):450-60. PubMed ID: 26295797 [TBL] [Abstract][Full Text] [Related]
40. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]